AUPHHealthcare · BiotechnologyThe 7 Wall Street analysts covering Aurinia Pharmaceuticals, Inc. hold a median 12-month price target of $18 — +5.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 4 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Aurinia Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (22): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
As of 30 October 2026, our factor model ranks Aurinia 97.9 of 100 across roughly 4,600 US stocks, fourth of 535 biotechs. Value (99.1), Quality (96.8) and Low Volatility (98.9) carry it: the shares cost little for what the business earns, and the price path is among the steadiest we track. The main drag is Investment/Accruals at 22.1, a family that flags reported profit not yet arrived as cash.
The Street's average target of $18 compares with a close of $16.65 on 30 October 2026; five of seven analysts rate the shares Buy, two Hold. The bigger gap is inside our own data: trailing P/E is 7.3, forward P/E is 14.3. The trailing figure includes the December 2025 quarter, which reported net income of $210.8M on sales of $77.1M.
That reading would turn if cash flow caught up with reported profit: in the four quarters to 30 June 2026, operating cash flow was $175.2M against net income of $314.1M. Estimates as of 27 October 2026 are split, with the current-year consensus of $0.948 per share down 0.2% in 90 days while next year's $1.168 is up 5.5%. The third-quarter report on 30 October 2026 delivered EPS of $0.23 against a $0.20 consensus and revenue of $83.7M.
As of 31 Oct 2026The bullish and bearish analyst opinions on AUPH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +5.1% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Nov 2026 | RBC Capital | Maintains | Sector Perform | $16 → $18 |
| 21 Oct 2026 | TD Cowen | Maintains | Buy | $17 → $18 |
| 7 Aug 2026 | RBC Capital | Maintains | Sector Perform | $15 → $16 |
| 7 Aug 2026 | RBC Capital | Maintains | Sector Perform | — |
| 3 Dec 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 3 Dec 2025 | Leerink Partners | Downgrade | Market Perform | $15 → $16 |
| 7 Nov 2025 | Jefferies | Upgrade | Buy | — |
| 5 Nov 2025 | RBC Capital | Downgrade | Sector Perform | — |
| 1 Aug 2025 | RBC Capital | Maintains | Outperform | — |
| 30 July 2025 | HC Wainwright & Co. | Assumes | Buy | $17 |
| 16 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 9 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 6 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Feb 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 22 Feb 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Feb 2024 | RBC Capital | Maintains | Outperform | — |
| 22 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | $14 → $15 |
| 7 Aug 2023 | HC Wainwright& Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AUPH appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Aurinia Pharmaceuticals, Inc. returned +20.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 63% of US stocks
Cheaper than 18% of US stocks
Cheaper than 27% of US stocks
Cheaper than 39% of US stocks
Higher than 61% of US stocks
Higher than 37% of US stocks
Higher than 97% of US stocks
Higher than 93% of US stocks
Higher than 99% of US stocks
Higher than 94% of US stocks
Higher than 97% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aurinia Pharmaceuticals, Inc. has a market value of $2.2B and an enterprise value of $1.7B.
Revenue in the twelve months to 30 June 2026: $311.5M. The latest quarter grew 13.9% year on year.
Net income over the same four quarters: $314.1M, a 100.8% net margin.
Diluted earnings per share, trailing twelve months: $2.29.
Free cash flow in the twelve months to 30 June 2026: $175.1M.
Aurinia Pharmaceuticals, Inc. spent $83.6M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 7.3×; forward P/E: 14.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Aurinia Pharmaceuticals, Inc. employs 128 people — $2.4M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aurinia Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Aurinia Pharmaceuticals reported quarterly earnings of $0.23 per share, above the Zacks Consensus Estimate of $0.20. Earnings were $0.23 per share in the year-ago quarter.
Why it matters — AUPH watchers may note that the reported quarterly earnings exceeded the consensus estimate.
Aurinia Pharmaceuticals reported third-quarter and nine-month 2026 results, with total revenue of $83.7 million and $244.6 million, respectively, up 14% and 19% from the same periods in 2025. The company also provided an update on recent business progress.
Why it matters — The results provide AUPH watchers with an update on revenue growth across the reported periods and the company’s recent business progress.
Zacks Investment Research says Aurinia Pharmaceuticals does not have the combination of two key ingredients associated with a likely earnings beat ahead of its upcoming Q3 report. The headline says Q3 earnings are expected to decline.
Why it matters — AUPH watchers may note the preview's expectation of declining Q3 earnings and its view on the likelihood of an earnings beat.
Zacks Investment Research highlights its Style Scores as a feature of Zacks Premium, saying they can help investors find stocks across value, growth, and momentum styles. The headline describes Aurinia Pharmaceuticals as a long-term growth stock.
Why it matters — AUPH watchers may note the article’s growth-stock framing and its reference to Zacks’ stock-screening research feature.
Zacks Investment Research discusses its Style Scores as a way for investors to find stocks rated highly for their investing style, and frames Aurinia Pharmaceuticals as a top momentum stock for the long term.
Why it matters — AUPH watchers may note the article's characterization of the stock through Zacks' momentum-style framing.
The 7 Wall Street analysts covering Aurinia Pharmaceuticals, Inc. have a median 12-month price target of $18, with estimates ranging from $16 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Aurinia Pharmaceuticals, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aurinia Pharmaceuticals, Inc. 98 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Aurinia Pharmaceuticals, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +5.1% from the last close, and Ticker Nerd's factor model ranks Aurinia Pharmaceuticals, Inc. 98 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aurinia Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AUPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $21 over the next 12 months.
Aurinia Pharmaceuticals, Inc. returned +20.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Aurinia Pharmaceuticals is a biopharmaceutical company with 128 employees, based in Edmonton, Canada. It develops and sells LUPKYNIS, an oral treatment for adults with active lupus nephritis, a kidney complication of lupus, in markets that include the United States and Japan.
The most recent item we track (Zacks Investment Research, 30 Oct 2026): "Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates". Aurinia Pharmaceuticals reported quarterly earnings of $0.23 per share, above the Zacks Consensus Estimate of $0.20. Earnings were $0.23 per share in the year-ago quarter.
Aurinia Pharmaceuticals is a biopharmaceutical company with 128 employees, based in Edmonton, Canada. It develops and sells LUPKYNIS, an oral treatment for adults with active lupus nephritis, a kidney complication of lupus, in markets that include the United States and Japan. The pipeline holds aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for autoimmune disease. Revenue for the twelve months to 30 June 2026 was $311.5M.
CEO Mr. Kevin C. Tang · 128 employees · Canada · https://www.auriniapharma.com
